Cambridge Healthtech Institute’s Second Annual

Preclinical and Translational Immuno-Oncology

Predictive Preclinical Models for Cancer Immunotherapy
August 29-30, 2017 | Sheraton Boston | Boston, MA

The recent advancements in immunotherapies, such as immune checkpoint modulators, bispecific antibodies, and adoptive T cell transfer, are shifting the way cancer patients are treated. Rapid development of novel immuno-oncology programs is creating the need for predictive preclinical models and translational strategies to understand combination cancer therapy, study responses to cancer immunotherapy, and identify novel biomarkers and targets. Please join Cambridge Healthtech Institute’s Second Annual Preclinical and Translational Immuno-Oncology meeting and learn about new clinically-relevant models for screening IO therapies and translational strategies to support clinical IO programs.

Preliminary Agenda


Accelerating Immuno-Oncology Drug Candidate Selection and Optimization: Dissecting Cancer Immunity Cycle through Quantitative and Advanced Immune Assay Technology Platforms

Litao Zhang, Ph.D., Vice President, Leads Discovery and Optimization, Bristol-Myers Squibb

Profiling Protein Signaling and Functional Response of Checkpoint Inhibitor and Combination Treatments in Patient-Derived Tumor Immune Cell Co-Culture Models

Christophe Sachse, Ph.D., Site Head Berlin, NMI TT Pharmaservices


Understanding the Tumor Microenvironment: Insights from Studying Mouse Tumor Models

Zhao Chen, Ph.D., Investigator III, Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research

Humanized Mouse Models for Preclinical Testing of Immune Checkpoint Modulators

Ella Ioffe, Ph.D., Associate Director, Immuno-Oncology, Regeneron Pharmaceuticals

Evaluating Anti-Tumor Immune Responses in Preclinical Mouse Models

Marcus Bosenberg, M.D., Ph.D., Associate Professor, Dermatology and Pathology, Yale School of Medicine; Co-Leader, Genomics, Genetics and Epigenetics Program, Yale Cancer Center

EMERGING INVESTIGATOR: Using Radiation to Elicit in situ Tumor Vaccination

Zachary Morris, Ph.D., Assistant Professor, Human Oncology, University of Wisconsin School of Medicine and Public Health


Advances, Challenges and Future of Translational Systems Pharmacology in Cancer Immunotherapy

Sihem Bihorel, MS, Pharm.D., Ph.D., Assistant Professor, Department of Pharmaceutics, College of Pharmacy, University of Florida

Generating Translational Hypotheses to Guide Development of IO Therapies

Laurence Menard, Ph.D., Senior Research Investigator, Bristol-Myers Squibb

EMERGING INVESTIGATOR: Quantifying Non-Self in Cancer

Benjamin Greenbaum, Ph.D., Assistant Professor, Medicine, Oncological Sciences, and Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences

For exhibit & sponsorship opportunities, please contact:

Rod Eymael
Manager, Business Development

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today